Articles

SAHPRA HIV treatment approval: Lenacapavir's impact on South Africa

Lenacapavir's recent approval by SAHPRA marks a significant advancement in HIV treatment options for South Africans, promising improved patient outcomes.

COFEPRIS Generics Approval: What You Need to Know About the New Streamlined Process

Learn how COFEPRIS's updated generics approval process simplifies access to vital medications, enhancing availability for patients in need.

ANVISA Risk-Based Inspection: What You Need to Know

Learn how ANVISA's Risk-Based Inspection enhances drug safety and compliance, streamlining processes for pharmaceutical manufacturers and protecting patient health.

Clinical Trial Outsourcing in Brazil & Mexico: Market Analysis 2024

This article analyzes the 2024 market for clinical trial outsourcing in Brazil and Mexico, focusing on drug development opportunities and regulatory challenges.

ANVISA Approval Immunotherapy Melanoma: What You Need to Know

ANVISA has approved immunotherapy for melanoma, offering new hope for patients. Explore the implications and benefits of this innovative treatment.

APAC KRAS Inhibitors: Elisrasib’s Promise in Advanced NSCLC

Elisrasib emerges as a promising KRAS inhibitor, revolutionizing treatment options for advanced NSCLC in the APAC region.

PMDA SAKIGAKE Designation: Accelerating Novel Cardiovascular Drug Approvals

Explore the impact of PMDA SAKIGAKE Designation on speeding up the approval process for groundbreaking cardiovascular drugs, including CardioX.

Radioligand Therapies for Prostate Cancer: Market Access and Clinical Insights in APAC

This article delves into the landscape of radioligand therapies for prostate cancer, focusing on market access and clinical insights across the APAC region.

NMPA Priority Review Pathway: What You Need to Know About Innovative Drug Approvals

Learn how the NMPA Priority Review Pathway accelerates innovative drug approvals, enhancing access to cutting-edge therapies for patients with critical conditions.

Biosimilar Market Growth Japan: Impact of PMDA's 2024 Interchangeability Guidelines

This article examines how the PMDA's 2024 interchangeability guidelines will influence the growth of the biosimilar market in Japan, focusing on drugs like Adalimumab.

NMPA Approval Oncology Drugs: Accelerated & Conditional Pathways Explained

This article delves into the NMPA's accelerated and conditional pathways for oncology drugs, highlighting their significance in expediting approvals for critical treatments.

HSA Clinical Trial Modernization: Singapore's New Framework for CITDs

Singapore's innovative framework for Clinical Investigation of Therapeutic Devices (CITDs) aims to modernize clinical trials, enhancing drug safety and efficacy.

NMPA Accelerated Approval Pathway: Impact on China's Innovative Drug Market

The NMPA Accelerated Approval Pathway is transforming China's innovative drug market, expediting access to essential cancer therapies and fostering innovation.

NMPA Expedited Approval Oncology: Impact on Cancer Drug Access in China

The NMPA's expedited approval process is transforming cancer drug access in China, significantly impacting treatments like osimertinib for lung cancer patients.

AI in Drug Discovery Japan: What You Need to Know

Discover the impact of AI on drug discovery in Japan, highlighting advancements in treatments such as Ozanimod for multiple sclerosis and their implications.